Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481549 | 0.81 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL5481924 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL5477821 | 0.77 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL5481545 | 0.64 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Isoxanthopterin SCHEMBL9148336 | 0.63 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL8723557 | 0.63 | MPO (0.54) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL3946766 | 0.60 | KDM4E (0.45) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL15752003 | 0.60 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| SCHEMBL24574329 | 0.59 | HSD17B10 (0.67) | KDM4EALDH1A1HSD17B10AKR1B1MEN1 | |
| SCHEMBL23028910 | 0.59 | HSD17B10 (0.67) | KDM4EALDH1A1HSD17B10AKR1B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419158-A1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Astrazeneca AB (SE) | 2004-05-19 | — | — | EP | claimed |
| WO-2003024966-A1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-27 | — | — | WO | claimed |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | CCR5, CXCR3, CCR2 | KDM4E 2810/4885ALDH1A1 1530/4885HSD17B10 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.